Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,293.72 +16.21 (+0.31%) Dow
38,646.54 -39.78 (-0.10%) Nasdaq
16,842.37 +107.36 (+0.64%) Bitcoin USD
70,229.52 +2,181.80 (+3.21%) CMC Crypto 200
1,502.88 +34.95 (+2.38%)
BHVN Oct 2024 30.000 call
| Previous close | 7.55 |
| Open | 6.20 |
| Bid | 7.30 |
| Ask | 11.50 |
| Strike | 30.00 |
| Expiry date | 2024-10-18 |
| Day's range | 6.20 - 7.84 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
PR NewswireBiohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of Biohaven's
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
GuruFocus.comDirector Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
On May 13, 2024, Gregory Bailey, Director of Biohaven Ltd (NYSE:BHVN), purchased 15,000 shares of the company.
